ACIU
AC Immune S.A.
NASDAQ · CHHealthcareBiotechnology
$2.25+2.27%
Price as of Jul 20, 2026
ACIU profitability
AC Immune S.A. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 100.0%
- EBITDA margin
- -1740.8%
- EBIT margin
- -1749.0%
- Net margin
- -1788.8%
- Free cash flow margin
- -1375.6%
Returns
- Return on equity
- -210.0%
- Return on assets
- -48.2%
- Return on invested capital
- -180.7%
- Asset turnover
- 0.03x
Cash efficiency
- Cash from operations
- -$62.4M
- Cash per share
- $0.91
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.